Immuneering Corporation (IMRX)
IMRX Stock Price Chart
Explore Immuneering Corporation interactive price chart. Choose custom timeframes to analyze IMRX price movements and trends.
IMRX Company Profile
Discover essential business fundamentals and corporate details for Immuneering Corporation (IMRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Jul 2021
Employees
54.00
Website
https://immuneering.comCEO
Benjamin J. Zeskind
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Financial Timeline
Browse a chronological timeline of Immuneering Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.35.
Earnings released on 13 Aug 2025
EPS came in at -$0.40 matching the estimated -$0.40.
Earnings released on 5 May 2025
EPS came in at -$0.42 falling short of the estimated -$0.41 by -2.44%.
Earnings released on 20 Mar 2025
EPS came in at -$0.58 falling short of the estimated -$0.42 by -38.10%.
Earnings released on 13 Nov 2024
EPS came in at -$0.49 surpassing the estimated -$0.54 by +9.26%.
Earnings released on 6 Aug 2024
EPS came in at -$0.47 surpassing the estimated -$0.51 by +7.84%.
Earnings released on 7 May 2024
EPS came in at -$0.49 falling short of the estimated -$0.45 by -8.89%.
Earnings released on 1 Mar 2024
EPS came in at -$0.52 falling short of the estimated -$0.48 by -8.33%, while revenue for the quarter reached -$94.42M .
Earnings released on 9 Nov 2023
EPS came in at -$0.43 surpassing the estimated -$0.51 by +15.69%.
Earnings released on 3 Aug 2023
EPS came in at -$0.43 surpassing the estimated -$0.54 by +20.37%, while revenue for the quarter reached $94.42M .
Earnings released on 4 May 2023
EPS came in at -$0.51 surpassing the estimated -$0.54 by +5.56%.
Earnings released on 6 Mar 2023
EPS came in at -$0.50 surpassing the estimated -$0.58 by +13.79%, while revenue for the quarter reached $456.00 , missing expectations by -99.24%.
Earnings released on 10 Nov 2022
EPS came in at -$0.49 falling short of the estimated -$0.48 by -2.08%, while revenue for the quarter reached $38.38K , missing expectations by -74.97%.
Earnings released on 10 Aug 2022
EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $94.42K , missing expectations by -52.02%.
Earnings released on 10 May 2022
EPS came in at -$0.49 falling short of the estimated -$0.44 by -11.36%, while revenue for the quarter reached $183.70K , beating expectations by +0.93%.
Earnings released on 10 Mar 2022
EPS came in at -$0.42 falling short of the estimated -$0.39 by -7.69%, while revenue for the quarter reached $189.59K , missing expectations by -64.60%.
Earnings released on 9 Nov 2021
EPS came in at -$0.47 surpassing the estimated -$0.61 by +22.95%, while revenue for the quarter reached $482.13K , beating expectations by +46.10%.
Earnings released on 9 Sept 2021
EPS came in at -$1.61 falling short of the estimated -$1.44 by -11.81%, while revenue for the quarter reached $660.04K .
Earnings released on 30 Jul 2021
EPS came in at -$0.46 , while revenue for the quarter reached $748.20K .
Earnings released on 31 Dec 2020
EPS came in at -$0.43 , while revenue for the quarter reached $665.08K .
Earnings released on 30 Sept 2020
EPS came in at -$0.33 , while revenue for the quarter reached $682.57K .
IMRX Stock Performance
Access detailed IMRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.